Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...

October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung...

Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor...

Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®)...

HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023 Strategic realignment to focus resources on ongoing...

Clinically active and well tolerated in patients with solid tumorsFavorable safety profile emerging: 22% of patients experienced Grade 1-2 cytokine release syndrome (CRS); no Grade 3 or higher CRSOne...

SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...

Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trialsEncouraging profile of tolerability and activity seen at...

Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors ...

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...